Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company, has announced a clinical collaboration with Merck subsidiary, MSD, a global, clinical-stage biotechnology company, it was reported on Monday.
The collaboration is aimed at assessing the combination of Ascentage Pharma's MDM2-p53 inhibitor, APG-115, and Merck's KEYTRUDA (pembrolizumab) intended for the treatment of patients with advanced solid tumours.
Under the agreement, Ascentage is to support an open-label, multicentre, phase Ib/II study (NCT03611868) intended to assess the safety and efficacy of both the products in multiple cohorts of solid tumours. The Phase II part of the study has commenced and is likely to enrol 80 patients at multiple sites in the United States. Both parties are to use a joint development committee to exchange information about the study.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study